Modeling the Cost-effectiveness of Esophageal Cancer Screening in China

Table 6 Summary of simulated cumulative EC incidence and mortality among different screening strategies

Age	Strategy	CI (per 100,000)	CM (per 100,000)	RCI (%)		RCM (%)
Age	Strategy	CI (per 100,000)	CM (per 100,000)	Scr* vs No_Scr	Scr_fol vs Scr_nfol	Scr* vs No_Scr	Scr_fol vs Scr_nfol
40–44	Non_scr	1010.62	776.76	–	–	–	–
	Scr_nfol	711.21	555.45	− 29.63	–	− 28.49	–
	Scr_fol	708.61	553.32	− 29.88	− 0.37	− 28.77	− 0.38
45–49	Non_scr	1010.04	778.32	–	–	–	–
	Scr_nfol	719.08	587.97	− 28.81	–	− 24.46	–
	Scr_fol	708.81	579.22	− 29.82	− 1.43	− 25.58	− 1.49
50–54	Non_scr	994.97	766.49	–	–	–	–
	Scr_nfol	726.70	642.84	− 26.96	–	− 16.13	–
	Scr_fol	701.17	619.77	− 29.53	− 3.51	− 19.14	− 3.59
55–59	Non_scr	962.42	746.15	–	–	–	–
	Scr_nfol	748.82	767.25	− 22.19	–	2.83	–
	Scr_fol	691.03	709.45	− 28.20	− 7.72	− 4.92	− 7.53
60–64	Non_scr	857.84	649.89	–	–	–	–
	Scr_nfol	720.35	829.78	− 16.03	–	27.68	–
	Scr_fol	637.03	738.52	− 25.74	− 11.57	13.64	− 11.00
65–69	Non_scr	710.26	512.38	–	–	–	–
	Scr_nfol	696.12	952.77	− 1.99	–	85.95	–
	Scr_fol	576.12	806.34	− 18.89	− 17.24	57.37	− 15.37

Scr_fol screening with follow-up, Scr_nfol screening without follow-up, Non_scr nonscreening, Scr* screening with or without follow-up, CI cumulative EC incidence, CM cumulative EC mortality, RCI reduction in cumulative incidence compared to an alternative strategy, RCM reduction in cumulative mortality compared to an alternative strategy

ISSN: 1478-7547